BDBM50024217 CHEMBL3325537::US9630929, Example 85

SMILES CN1CC[C@@H]([C@@H](COc2cc(F)c(cc2F)S(=O)(=O)Nc2ncns2)C1)c1ccc(Cl)cc1

InChI Key InChIKey=LDZNFFGWKHAEMM-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 50024217   

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 4nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2016
Entry Details Article
PubMed
TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 4.80nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 100nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 140nMAssay Description:Inhibition of CYP3A4 (unknown origin) using midazolam substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2016
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 270nMAssay Description:Inhibition of CYP2D6 (unknown origin) using bufuralol substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2016
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 880nMAssay Description:Inhibition of CYP2C9 (unknown origin) using diclofenac substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2016
Entry Details Article
PubMed
TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human Nav1.5 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2016
Entry Details Article
PubMed
TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 1.00E+4nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetCytochrome P450 2C19(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin) using omeprazole substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/6/2016
Entry Details Article
PubMed
TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50024217(CHEMBL3325537 | US9630929, Example 85)
Affinity DataIC50: 1.00E+4nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent